文献速递慢性肾脏病

肾脏病研究优先领域设定研究中利益相关方参与及范围的演变:系统综述

Evolution of Stakeholder Involvement and Scope of Research Priority-Setting Studies in Kidney Disease: A Systematic Review.
PubMed 文献 · Am J Kidney Dis · 2026-10-05

本系统综述纳入34项肾脏病研究优先领域设定研究,涉及超过3609名利益相关方。2015年后患者和照护者明确参与比例从25%(4/16)升至89%(16/18),研究优先领域从单一关注医学治疗扩展至心理社会支持、健康教育、卫生服务及公平可及性等领域。但中低收入地区研究、研究终端用户持续纳入及报告完整性仍存在显著缺口。

要点

  • 2015年后患者和照护者参与优先领域设定的比例升至89%(16/18),较2015年前的25%(4/16)明显提高。
  • 研究优先领域从关注医学治疗扩展至心理社会与教育支持、卫生服务及公平可及性等多个领域。
  • 中低收入地区研究缺失、研究终端用户参与不足及报告完整性仍是主要缺口。

核心结论

  • 肾脏病研究优先领域设定研究日益增多,患者和照护者参与增加,研究范围随时间扩展,但在中低收入地区研究、研究终端用户持续纳入及报告完整性方面仍存在显著缺口。

研究设计与样本

  • 系统综述,检索Medline、EMBASE、PsycINFO和CINAHL自建库至2025年1月20日,纳入34项研究,涉及超过3609名利益相关方(1976名临床医生、768名患者、114名照护者、232名研究者、63名政策制定者)。

主要发现

  • 8项研究为多国研究,其余在5个国家开展且均为高收入国家;几乎所有研究发表于2000年后,超过半数发表于2015年后。
  • 2015年前患者和照护者明确参与比例为25%(4/16),2015年及以后为89%(16/18);明确使用优先领域设定框架的比例分别为38%(6/16)和50%(9/18)。
  • REPRISE清单报告在领域层面随时间有所改善,但总体仍存在约30%的缺口。
  • 研究优先领域从共同关注医学治疗扩展至心理社会与教育支持、卫生服务及公平可及性等领域。

临床怎么用

  • 开展肾脏病研究优先领域设定时应持续纳入患者和照护者等研究终端用户,并采用REPRISE清单提高报告完整性。

局限性

  • 仅纳入同行评议的英文发表文献。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Kidney research that explicitly includes patient and caregiver perspectives has been identified as a priority. This study assessed the evolution of research studies on priority-setting in kidney disease, including the clinical scope of priorities and the extent of stakeholder involvement. STUDY DESIGN: Systematic review. SETTING & PARTICIPANTS: Studies conducted to identify research priorities in kidney disease that elicited the perspectives of patients, caregivers, researchers, clinicians, or policymakers. SELECTION CRITERIA FOR STUDIES: Medline, EMBASE, PsycINFO, and CINAHL were searched from database inception to January 20, 2025. DATA EXTRACTION: Full texts assessed independently by 2 reviewers. ANALYTICAL APPROACH: Descriptive synthesis. RESULTS: Thirty-four studies involving more than 3,609 stakeholders (1,976 clinicians, 768 patients, 114 caregivers, 232 researchers, and 63 policymakers) were included. Eight studies were multinational, with the remaining conducted in 5 countries (all high income). Almost all were published since 2000, with over half since 2015. Explicit patient and caregiver involvement increased from 25% (4 of 16) before 2015 to 89% (16 of 18) in 2015 or later, with a priority-setting framework explicitly used in 38% (6 of 16) of studies before 2015, and 50% (9 of 18) of studies in 2015 or later. Reporting Guideline for Priority Setting of Health Research (REPRISE) checklist reporting showed some increase in domain-level reporting over time with substantial gaps remaining (overall around 30%). Temporal trends demonstrated a broadening of research priorities from a common singular focus on medical treatments toward inclusion of domains such as psychosocial and educational supports, health services, and equitable access to care across the spectrum of chronic kidney disease. LIMITATIONS: Restricted to peer-reviewed, English-language publications. CONCLUSIONS: Research priority-setting studies in kidney disease are becoming more common, are increasingly including patients/caregivers, and have become broader in scope over time. However, significant gaps remain related to studies in low- and middle-income settings, the consistent inclusion of end-users of research, and the completeness of reporting. PLAIN-LANGUAGE SUMMARY: This review looked at studies of research priority setting in kidney disease over the past 25 years. It found 34 studies involving more than 3,609 stakeholders (patients, caregivers, clinicians, researchers, and policymakers). All were done in high-income countries. Patient and caregiver involvement in deciding priority research topics has increased, the scope has broadened beyond medical treatments to include education, psychosocial support, health services, and equitable access to care, and there are fewer gaps in the reporting of how the studies were done. However, the high-priority kidney research topics in low- and middle- income countries remain uncertain. Also, many studies still do not engage the end-users of research, patients and caregivers, and many lack clarity regarding their study design and reporting.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Coghlan D, Jauré A, Craig JC, et al. Evolution of Stakeholder Involvement and Scope of Research Priority-Setting Studies in Kidney Disease: A Systematic Review. Am J Kidney Dis. 2026. PMID: 42833571. doi:10.1053/j.ajkd.2026.06.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。